What is glioblastoma and how effective is the new experimental glioblastoma vaccine?

A new experimental glioblastoma vaccine has been developed and a phase 1b clinical trial shows that the treatment effectively prolongs patient survival.

The glioblastoma vaccine was developed by Jefferson and Imvax and the Phase 1b clinical trial shows that the treatment was well tolerated by patients, slowed tumor recurrence and prolonged patient survival.

What is glioblastoma?

As the most aggressive type of primary brain cancer, it has a prognosis of 11 to 15 months with standard treatment.

The results of the test

The results showed that patients who received the glioblastoma vaccine had longer progression-free survival and overall survival than the control group. These are two common measures of successful cancer treatment. No adverse events related to the vaccine were observed.

The immunologist Dr. Craig Hooper, PhD, professor of cancer biology at Sidney Kimmel Cancer Center and co-founder and scientific director of Imvax, explained: "As a result of the combined effects of antisense and of IGF-1R irradiation, our evidence shows that chamber tumor cells release antigens that, together with the immunomodulatory AS-ODN, diffuse out of the chamber into the patient's body and activate the immune system against tumor cells of the brain. "

David Andrews, MD, professor of neurosurgery at the Vickie Institute of Neuroscience & Jack Farber and co-founder, Acting Chief Medical Officer and CEO of Imvax, added, "The answer we see in some patients is very encouraging. We look forward to starting a Phase II trial later this year to confirm these Phase 1b results. "

The future treatment of glioblastoma

Robert Rosenwbader, MD, MBA, President and CEO of the Vickie Institute of Neuroscience & Jack Farber, concluded, "That's why academic medical centers such as Jefferson excel with innovations. that improve lives. The depth of cellular and molecular knowledge in laboratory science generates the design of the treatments most likely to succeed. When basic laboratory science and clinical research combine with a pbadionate need to improve the lives of our patients and their families, we are developing incredible advances in treatment paradigms. "